| Cat.No. | Name | Information |
|---|---|---|
| M8959 | BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) | BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) is an inhibitor of PD-1/PD-L1 protein/protein interaction with an IC50 of 6 to 100 nM. |
| M6101 | Atezolizumab | Atezolizumab (atezolizumab) is a humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 signaling with PD-1 and B7-1 and restores tumor-specific T-cell immunity. However, it does not affect the interaction of PD-L2 with PD-1. Atezolizumab reacts with murine PD-L1 (for human and non-humanized mice). |
| M3813 | Avelumab (MSB0010718C) | Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Avelumab recognizes murine PD-L1 |
| M6100 | Nivolumab | Nivolumab (nabumab) is a fully humanized IgG4 monoclonal antibody against PD-1. It has immune checkpoint inhibitory activity and antitumor activity; MW: 143.597 KD.(for human-derived mice). |
| M5144 | BMS202 | Bms-202 is an effective non-peptide PD-1/PD-L complex inhibitor with IC50 of 18 nM and KD of 8 μM. Bms-202 directly binds to PD-L1 and blocks the human PD-1/PD-L interaction. Bms-202 has antitumor activity. |
| M6102 | Pembrolizumab | Pembrolizumab (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. It has immune checkpoint inhibitory activity and antitumor activity. MW: 146.286 KD.(Pembrolizumab does not recognize murine PD-1 protein, humanized mice or mice expressing human PD-1 gene are required). |
| M25342 | Pucotenlimab | Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor. |
| M25157 | Ivonescimab | Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research. |
| M25142 | Tuvonralimab | Tuvonralimab (PSB-205; QL1706) is an anti-CTLA-4 IgG1 monoclonal antibody that can be used in tumor-related studies. |
| M25137 | Rulonilimab | Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity. |
| M25115 | Cadonilimab | Cadonilimab (AK104) is a targeting PD1/CTLA4 IgG1 scaffold Fc-engineered humanized bispecific antibody. Cadonilimab can be used for researching metastatic cervical cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC). |
| M25110 | Nofazinlimab | Nofazinlimab (CS1003）, which is a humanized IgG4 PD-1 mAb， bound to recombinant human, cynomolgus monkey, and mouse PD-1 with EC50 values of 0.1757, 0.2459, and 0.3664 nM, respectively. Nofazinlimab (CS1003）blocked PD-1 interaction with its ligands, dose-dependently enhanced T cell proliferation and secretion of cytokines (IL-2 and IFN-γ) to the levels comparable to Pembrolizumab. Nofazinlimab can be used for unresectable hepatocellular carcinoma (uHCC) research. |
| M25087 | Penpulimab | Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities. |
| M25073 | Socazolimab | Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma. |
| M25061 | Zimberelimab | Zimberelimab is a fully human IgG4 anti-PD-1 monoclonal antibody with high affinity and selectivity. Zimberelimab shows antitumor activities and can be used for various cancers research including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma. |
| M25059 | Sugemalimab | Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research. |
| M25031 | Adebrelimab | Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC). |
| M25029 | Tebotelimab | Tebotelimab (MGD-013) is a human IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity. |
| M25016 | Serplulimab | Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody. Serplulimab can be used in research of small cell lung cancer. |
| M24992 | Cosibelimab | Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1+ cell lines, including lymphoma cells. |
| M24953 | Balstilimab | Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1. |
| M24923 | Envafolimab | Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors. |
| M24903 | Retifanlimab | Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA). |
| M24902 | Sintilimab | Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer. |
| M24876 | Dostarlimab | Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively. |
| M24869 | Onvatilimab | Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
